Kazia Therapeutics Limited: KAZIA THERAPEUTICS REPORTS PROMI

SYDNEY, Aug. 5, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of promising new

Related Keywords

New York , United States , Australia , Memorial Sloan Kettering Cancer Center , Canada , Sydney , New South Wales , Toronto , Ontario , American , Jonathan Yang , James Garner , Jane Lowe , Hardestyp Nakaji , Joe Green , T Jonathan Yang , Iain Ross , Prnewswire Kazia Therapeutics Limited , Genentech , American Society For Clinical Oncology , Society For Neuro , Ir Department , Kazia Therapeutics Limited , International Towers , Kazia Therapeutics , Therapeutics Limited , Brain Metastases , American Society , Clinical Oncology , Metastatic Disease , Radiation Oncology , Principal Investigator , Study Rationale , Multimodality Approaches , Secondary Brain Tumors , More Information , Please Contact , Orphan Drug Designation , Fast Track Designation , Rare Pediatric Disease Designation , Orphan Designation , Annual Report , Chief Executive Officer , Nat Rev Disease Primers , Iain Ross Chairman , James Garner Chief Executive Officer , Kazia , Herapeutics , Imited , Azia , Reports , Romising , Interim , Data , Rom , Combination , Study , Paxalisib , Ith , Radiotherapy , Treatment , Rain , Metastases ,